Karuna Therapeutics, Inc.

Report azionario NasdaqGM:KRTX

Capitalizzazione di mercato: US$12.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Karuna Therapeutics Performance degli utili passati

Criteri Il passato verificati 0/6

Gli utili di Karuna Therapeutics sono diminuiti a un tasso medio annuo di -51.9%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 33.8%. I ricavi sono cresciuti crescere a un tasso medio annuo di 46.1%.

Informazioni chiave

-51.90%

Tasso di crescita degli utili

105.14%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.04%
Tasso di crescita dei ricavi46.13%
Rendimento del capitale proprio-34.58%
Margine netto-66,311.93%
Ultimo aggiornamento sugli utili31 Dec 2023

Aggiornamenti sulle prestazioni recenti

Recent updates

Seeking Alpha • Feb 18

Karuna Therapeutics: Getting Sold Short

Summary Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination. Some shareholders are suing to prevent the acquisition of Karuna by Bristol-Myers Squibb. Also, the vote is outstanding. The 10% or so deal spread seems small. While the chance that the deal falls through would be bad for the short-term performance of Karuna, it may be a buying moment considering the imminent release and size of markets. Read the full article on Seeking Alpha
Seeking Alpha • Sep 09

Karuna Therapeutics: This Ship Has Sailed

Summary Karuna produced excellent data from its phase 3 trial. They have a boatload of cash. Speaking of boats, however, this ship has already sailed. Since my last coverage of Karuna Therapeutics, Inc. (KRTX) just over a year back, the stock has nearly tripled after posting strong results from its schizophrenia trial, meeting the primary endpoint of that trial. That was a month back, and even though the company took the opportunity to carry out a massive $600mn secondary, the dilution hasn’t put a dent in public enthusiasm. The stock is still going strong, although it is back down a few notches. From my previous coverage of the company, they were running a 246-patient phase 3 trial called EMERGENT-2, and 3 more phase 3 trials in the EMERGENT series, in their lead candidate KarXT in acutely psychotic patients with a DSM-5 diagnosis of schizophrenia. KarXT is a differentiated antipsychotic molecule that combines muscarinic-agonist xanomeline and muscarinic-antagonist trospium chloride together. While xanomeline works in the CNS, trospium helps avoid undesirable, cholinergic side effects that arise due to the stimulation of muscarinic receptors in peripheral tissues. The FDA has guided that “data from EMERGENT-1 [a phase 2 study], one successful Phase 3 efficacy and safety trial, and additional safety data to meet regulatory requirements would be acceptable to support NDA filing in schizophrenia.” The first two phase 3 studies were supposed to have toplined in early 2022. In August, the company announced positive data from the EMERGENT-2 trial. This was a double blind, placebo controlled trial done entirely in the United States. It enrolled 252 adult patients with a confirmed diagnosis of schizophrenia who were experiencing symptoms of psychosis. The primary endpoint was change from baseline in Positive and Negative Syndrome Scale ((PANSS)) total score, a scale for measuring schizophrenia symptom severity, of KarXT compared to placebo at Week 5. The trial resoundingly met its primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001). The trial also met key secondary endpoints. Data include: 2.9-point reduction in the PANSS positive subscale with KarXT compared to placebo (-6.8 KarXT vs. -3.9 placebo, p<0.0001). 1.8-point reduction in the PANSS negative subscale with KarXT compared to placebo (-3.4 KarXT vs. -1.6 placebo, p=0.0055). 2.2-point reduction in the PANSS negative Marder factor subscale with KarXT compared to placebo (-4.2 KarXT vs. -2.0 placebo, p=0.0022). The PANSS scores are used to measure positive symptoms (e.g., hallucinations or delusions) and negative symptoms (e.g., difficulty enjoying life or withdrawal from others) of schizophrenia. Benefit in the negative symptoms has historically been difficult to achieve. The trial’s Cohen’s d effect size of 0.61 compares well “to that of widely used and multibillion-dollar blockbusters Risperdal and Zyprexa (about a 0.5 effect size),” according to William Blair analysts. The drug was generally well-tolerated with little differentiation from placebo. There was transient increase in heart rate, which subsided as the trial ended. Importantly, KarXT was not associated with known side effects of current treatments. As FierceBiotech noted: The clinical trial studied KarXT, a xanomeline formulation designed to address the problems that led Lilly to give up on the molecule despite generating evidence of efficacy. Lilly found the M1 agonist improved cognition in Alzheimer’s disease patients in the 1990s, only for tolerability to stop the program. Karuna sought to address the tolerability problems by giving xanomeline with a peripherally restricted molecule that blocks receptors at the root of the issues without crossing the blood-brain barrier to limit efficacy.
Seeking Alpha • Aug 08

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Karuna Therapeutics press release (NASDAQ:KRTX): Q2 GAAP EPS of -$2.17 misses by $0.10. Revenue of $5.28M. The Company ended the quarter with $407.4 million in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as of December 31, 2021. The Company expects that current cash, cash equivalents and available-for-sale investment securities as of June 30, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements for at least 12 months following the potential NDA submission of KarXT for the treatment of psychosis in adults with schizophrenia. Shares +8.29% PM.
Seeking Alpha • Jun 26

Karuna Therapeutics: Front-Running KarXT Phase 3

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event. Despite cash balance issues and new clinical stage competitors, market  indicators suggest that investors are re-engaged.

Ripartizione dei ricavi e delle spese

Come Karuna Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGM:KRTX Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&amp;S
31 Dec 231-434131364
30 Sep 236-396108348
30 Jun 236-35495306
31 Mar 2311-31685266
31 Dec 2211-27675224
30 Sep 2242-22871203
30 Jun 2242-20265180
31 Mar 2237-17257152
31 Dec 2137-14452128
30 Sep 210-1404197
30 Jun 210-1083671
31 Mar 210-903357
31 Dec 200-692843
30 Sep 200-522333
30 Jun 200-432126
31 Mar 200-412222
31 Dec 190-442125
30 Sep 190-451826
30 Jun 190-421522
31 Mar 190-27717
31 Dec 180-18312

Guadagni di qualità: KRTX al momento non è redditizia.

Margine di profitto in crescita: KRTX al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: KRTX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 51.9% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di KRTX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: KRTX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 43% ).

Rendimento del capitale proprio

ROE elevato: KRTX ha un Return on Equity negativo ( -34.58% ), in quanto al momento non è redditizio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/03/18 14:34
Prezzo dell'azione a fine giornata2024/03/15 00:00
Utili2023/12/31
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Karuna Therapeutics, Inc. è coperta da 17 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Caroline PalomequeBerenberg
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research